Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,422

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

Open access
Ley, Timothy J., Mardis, Elaine R., Ding, Li, Fulton, Bob, McLellan, Michael D., Chen, Ken, Dooling, David, Dunford-Shore, Brian H., McGrath, Sean, Hickenbotham, Matthew, Cook, Lisa, Abbott, Rachel, Larson, David E., Koboldt, Dan C., Pohl, Craig, Smith, Scott, Hawkins, Amy, Abbott, Scott, Locke, Devin, Hillier, LaDeana W., Miner, Tracie, Fulton, Lucinda, Magrini, Vincent, Wylie, Todd, Glasscock, Jarret, Conyers, Joshua, Sander, Nathan, Shi, Xiaoqi, Osborne, John R., Minx, Patrick, Gordon, David, Chinwalla, Asif, Zhao, Yu, Ries, Rhonda E., Payton, Jacqueline E., Westervelt, Peter, Tomasson, Michael H., Watson, Mark, Baty, Jack, Ivanovich, Jennifer, Heath, Sharon, Shannon, William D., Nagarajan, Rakesh, Walter, Matthew J., Link, Daniel C., Graubert, Timothy A., DiPersio, John F., Wilson, Richard K.·2008·Nature
DOI 10.1038/nature07485
Open this paper in CoChat — free account

Abstract

Acute myeloid leukaemia is a highly malignant haematopoietic tumour that affects about 13,000 adults in the United States each year. The treatment of this disease has changed little in the past two decades, because most of the genetic events that initiate the disease remain undiscovered. Whole-genome sequencing is now possible at a reasonable cost and timeframe to use this approach for the unbiased discovery of tumour-specific somatic mutations that alter the protein-coding genes. Here we present the results obtained from sequencing a typical acute myeloid leukaemia genome, and its matched normal counterpart obtained from the same patient’s skin. We discovered ten genes with acquired mutations; two were previously described mutations that are thought to contribute to tumour progression, and eight were new mutations present in virtually all tumour cells at presentation and relapse, the function of which is not yet known. Our study establishes whole-genome sequencing as an unbiased method for discovering cancer-initiating mutations in previously unidentified genes that may respond to targeted therapies. The technologies that made it possible to characterize individual African and Chinese genomes have broad application in the biomedical field. A demonstration of what can be achieved in a medical context is the first comprehensive sequence of an individual cancer genome, for a patient with acute myeloid leukaemia. By comparing DNA from cancer and normal tissue from the same individual, ten mutations of possible relevance for pathogenesis were identified. As well as pointing to genes that may respond to targeted therapy, this work is a step towards the long-term goal of establishing the contextual relevance of such mutants, a process that will involve the analysis of many more personal genomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nature07485

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 25

  1. Jemal, A. et al. Cancer statistics, 2008. CA Cancer J. Clin. 58, 71–96 (2008) · DOI · Paper page
  2. Owen, C., Barnett, M. & Fitzgibbon, J. Familial myelodysplasia and acute myeloid leukaemia—a review. Br. J. Haematol. 140, 123–132 (2008) · DOI
  3. Mrozek, K., Marcucci, G., Paschka, P., Whitman, S. P. & Bloomfield, C. D. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 109, 431–448 (2007) · DOI · Paper page
  4. Loriaux, M. M. et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood 111, 4788–4796 (2008) · DOI
  5. Tomasson, M. H. et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 111, 4797–4808 (2008) · DOI
  6. Schoch, C. et al. Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc. Natl Acad. Sci. USA 99, 10008–10013 (2002) · DOI · Paper page
  7. Bullinger, L. et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 350, 1605–1616 (2004) · DOI · Paper page
  8. Mullighan, C. G. et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446, 758–764 (2007) · DOI · Paper page
  9. Mullighan, C. G. et al. BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453, 110–114 (2008) · DOI · Paper page
  10. Raghavan, M. et al. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res. 65, 375–378 (2005) · DOI · Paper page
  11. Paulsson, K. et al. High-resolution genome-wide array-based comparative genome hybridization reveals cryptic chromosome changes in AML and MDS cases with trisomy 8 as the sole cytogenetic aberration. Leukemia 20, 840–846 (2006) · DOI
  12. Rucker, F. G. et al. Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J. Clin. Oncol. 24, 3887–3894 (2006) · DOI
  13. Hillier, L. W. et al. Whole-genome sequencing and variant discovery in C. elegans . Nat. Methods 5, 183–188 (2008) · DOI · Paper page
  14. Byrd, J. C. et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100, 4325–4336 (2002) · DOI · Paper page
  15. Grimwade, D. et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 92, 2322–2333 (1998) · DOI · Paper page
  16. Mrozek, K., Heerema, N. A. & Bloomfield, C. D. Cytogenetics in acute leukemia. Blood Rev. 18, 115–136 (2004) · DOI · Paper page
  17. Wendl, M. C. & Wilson, R. K. Aspects of coverage in medical DNA sequencing. BMC Bioinformatics 9, 239 (2008) · DOI
  18. Li, H., Ruan, J. & Durbin, R. Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res doi: 10.1101/gr.078212.108 (in the press) · DOI · Paper page
  19. Quinlan, J. R. C4.5:Programs for Machine Learning 302 (Morgan Kaufmann Publishers, 1993)
  20. Link, D. C. et al. Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood 110, 1648–1655 (2007) · DOI
  21. Frohling, S. et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 12, 501–513 (2007) · DOI
  22. Levis, M. & Small, D. FLT3: ITDoes matter in leukemia. Leukemia 17, 1738–1752 (2003) · DOI · Paper page
  23. Thiede, C. et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107, 4011–4020 (2006) · DOI · Paper page
  24. den Besten, W., Kuo, M. L., Williams, R. T. & Sherr, C. J. Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein. Cell Cycle 4, 1593–1598 (2005) · DOI
  25. Kelly, L. M. et al. PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model. Proc. Natl Acad. Sci. USA 99, 8283–8288 (2002) · DOI · Paper page

Cited by

Metadata

Authors
Ley, T. J., Mardis, E. R., Ding, L., Fulton, B., McLellan, M. D., Chen, K., Dooling, D., Dunford-Shore, B. H., McGrath, S., Hickenbotham, M., Cook, L., Abbott, R., Larson, D. E., Koboldt, D. C., Pohl, C., Smith, S., Hawkins, A., Abbott, S., Locke, D., Hillier, L. W., Miner, T., Fulton, L., Magrini, V., Wylie, T., Glasscock, J., Conyers, J., Sander, N., Shi, X., Osborne, J. R., Minx, P., Gordon, D., Chinwalla, A., Zhao, Y., Ries, R. E., Payton, J. E., Westervelt, P., Tomasson, M. H., Watson, M., Baty, J., Ivanovich, J., Heath, S., Shannon, W. D., Nagarajan, R., Walter, M. J., Link, D. C., Graubert, T. A., DiPersio, J. F., & Wilson, R. K.
Venue
Nature
Publisher
Springer Science and Business Media LLC
Published
2008-11
Volume
456
Issue
7218
Pages
66-72
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
DOI
10.1038/nature07485
OpenAlex
W2153010521
Cited by
1,422
References
4
FWCI
84.91
Type
journal article
Language
en
Open access
hybrid
Licence
creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.